-$1.30 EPS Expected for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) This Quarter

Wall Street brokerages expect Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMGet Rating) to post earnings of ($1.30) per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Mirum Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.03) and the lowest estimate coming in at ($1.47). Mirum Pharmaceuticals reported earnings of ($1.68) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 22.6%. The firm is scheduled to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Mirum Pharmaceuticals will report full year earnings of ($5.01) per share for the current year, with EPS estimates ranging from ($6.01) to ($4.21). For the next year, analysts expect that the business will report earnings of ($3.32) per share, with EPS estimates ranging from ($4.48) to ($2.54). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Mirum Pharmaceuticals.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Rating) last announced its quarterly earnings results on Wednesday, March 9th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.31). The firm had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $76.60 million.

MIRM has been the topic of a number of research analyst reports. Raymond James upped their price target on Mirum Pharmaceuticals from $70.00 to $74.00 and gave the company a “strong-buy” rating in a report on Friday, March 11th. SVB Leerink upped their price target on Mirum Pharmaceuticals from $42.00 to $46.00 and gave the company an “outperform” rating in a report on Friday, January 28th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $49.60.

Shares of NASDAQ:MIRM opened at $27.50 on Friday. The company has a market cap of $872.58 million, a P/E ratio of -9.93 and a beta of 1.40. Mirum Pharmaceuticals has a 1 year low of $12.82 and a 1 year high of $28.65. The stock’s fifty day moving average price is $23.15 and its 200-day moving average price is $18.62.

A number of institutional investors and hedge funds have recently modified their holdings of MIRM. Morgan Stanley increased its position in Mirum Pharmaceuticals by 7,247.9% in the second quarter. Morgan Stanley now owns 45,116 shares of the company’s stock worth $781,000 after buying an additional 44,502 shares in the last quarter. Raymond James & Associates increased its position in Mirum Pharmaceuticals by 43.2% in the third quarter. Raymond James & Associates now owns 19,865 shares of the company’s stock worth $396,000 after buying an additional 5,991 shares in the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in Mirum Pharmaceuticals in the third quarter worth about $473,000. Los Angeles Capital Management LLC increased its position in Mirum Pharmaceuticals by 7.0% in the third quarter. Los Angeles Capital Management LLC now owns 22,410 shares of the company’s stock worth $446,000 after buying an additional 1,470 shares in the last quarter. Finally, BlackRock Inc. increased its position in Mirum Pharmaceuticals by 0.5% in the third quarter. BlackRock Inc. now owns 610,565 shares of the company’s stock worth $12,162,000 after buying an additional 2,831 shares in the last quarter. Institutional investors and hedge funds own 78.82% of the company’s stock.

Mirum Pharmaceuticals Company Profile (Get Rating)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

Featured Stories

Get a free copy of the Zacks research report on Mirum Pharmaceuticals (MIRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.